BeiGene wins expanded approval for tislelizumab in China

By The Science Advisory Board staff writers

March 17, 2022 -- BeiGene has received a new conditional approval from the China National Medical Products Administration (NMPA) for its tislelizumab anti-programmed cell death 1 (PD-1) monoclonal antibody.

The NMPA approved the use of tislelizumab as a treatment for advanced unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors in adult patients. The approval covers patients with advanced colorectal cancer who had been treated with fluoropyrimidine, oxaliplatin, and irinotecan, according to the vendor. It also covers patients with other advanced solid tumors who developed disease progression after prior treatment and have no satisfactory alternative treatment options, BeiGene said.

With the new approval, tislelizumab has now been cleared in China for seven indications, according to the firm.

Strand Therapuetics, BeiGene to develop mRNA platform tech
Strand Therapeutics and BeiGene have entered into an option and license agreement in order to develop and commercialize Strand's messenger RNA (mRNA)...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter